REGN
$582.52
Regeneron Pharmaceuticals
($3.22)
(.55%)
REGN
Earnings Whisper ®
N/A
3rd Quarter September 2020
Consensus:  $9.52
Revenue:  $2.12 Bil
Thursday
Nov 5
6:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when REGN reports earnings?
Beat
Meet
Miss

Where is REGN's stock price going from here?
Up
Flat
Down
Stock chart of REGN
Analysts
Summary of analysts' recommendations for REGN
Score
Grade
Pivots
Resistance
$601.24
$596.11
$589.31

$584.18

Support
$577.38
$572.25
$565.45
Tweet
Growth
Description
Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma and has preclinical programs in other diseases and disorders.
Peers
InterCeptBioMarin PharmaceuticalVertex PharmaceuticalsZoetisBristol-Myers SquibbJohnson & JohnsonMerck & Co.PfizerUltragenyx PharmaceuticalEli Lilly